The Journal of Immunology, Vol 142, Issue 8 2660-2669, Copyright © 1989 by American Association of Immunologists

ARTICLES

IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome

NK Damle and LV Doyle
Clinical Biology Department, CETUS Corporation, Emeryville, CA 94608.

When cultured with IL-2, human lymphoid cells acquire the ability to lyse various NK-resistant tumor targets. Due to their anti-tumor cytolytic effect, clinical trials with IL-2 alone or IL-2 + IL-2- activated killer (IAK) lymphocytes have been undertaken. However, infusion of therapeutically effective doses of IL-2 is associated with the development of systemic toxicity characterized by exaggerated endothelial permeability, also known as vascular leak syndrome. The present study was designed to examine the effects of IAK cells and their secreted products on vascular endothelial permeability by using an in vitro endothelial permeability model in which the flux of FITC- albumin across endothelial cell (EC) monolayers was measured. When endothelial monolayers were exposed to IAK cells for 2 h, significant increases in the transendothelial permeability to albumin were observed. Exposure of EC to lymphocytes cultured in the absence of IL-2 did not induce significant alteration in the endothelial permeability. In addition, neither culture supernatants of IAK cells nor purified recombinant cytokines, including IL-1 beta, IL-2, IL-3, IL-4, IL-6, TNF- alpha, GM-CSF, M-CSF, and IFN-gamma, had any effect on endothelial permeability in this model. Prior activation of EC with TNF-alpha did not alter the increased permeability induced by IAK cells or lack of it by nonactivated lymphocytes. Dexamethasone treatment of IAK cells abolished their anti-tumor cytolytic effect but only partially inhibited their ability to induce increased endothelial permeability. Pretreatment of IAK cells with mAb directed at the CD11a/CD18 (LFA-1) adhesion complex, and that of EC with mAb directed at the ICAM-1 molecule, inhibited the IAK cell-induced increase in endothelial permeability. These results demonstrate that direct cell-to-cell contact between IAK cells and EC is necessary and sufficient to cause increased endothelial permeability in this model system, and may therefore be an important factor contributing to the development of the vascular leak syndrome observed clinically.

This article has been cited by other articles:

				H. Guan, P. S. Nagarkatti, and M. Nagarkatti Blockade of Hyaluronan Inhibits IL-2-Induced Vascular Leak Syndrome and Maintains Effectiveness of IL-2 Treatment for Metastatic Melanoma J. Immunol., September 15, 2007; 179(6): 3715 - 3723. [Abstract] [Full Text] [PDF]

				A. E. M. Dirkx, M. G. A. oude Egbrink, J. Wagstaff, and A. W. Griffioen Monocyte/macrophage infiltration in tumors: modulators of angiogenesis J. Leukoc. Biol., December 1, 2006; 80(6): 1183 - 1196. [Abstract] [Full Text] [PDF]

				E. Assier, V. Jullien, J. Lefort, J.-L. Moreau, J. P. Di Santo, B. B. Vargaftig, J. R. Lapa e Silva, and J. Theze NK Cells and Polymorphonuclear Neutrophils Are Both Critical for IL-2-Induced Pulmonary Vascular Leak Syndrome J. Immunol., June 15, 2004; 172(12): 7661 - 7668. [Abstract] [Full Text] [PDF]

				P. Hu, M. Mizokami, G. Ruoff, L. A. Khawli, and A. L. Epstein Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity Blood, June 15, 2003; 101(12): 4853 - 4861. [Abstract] [Full Text] [PDF]

				A. L. Epstein, M. M. Mizokami, J. Li, P. Hu, and L. A. Khawli Identification of a Protein Fragment of Interleukin 2 Responsible for Vasopermeability J Natl Cancer Inst, May 21, 2003; 95(10): 741 - 749. [Abstract] [Full Text] [PDF]

				P. Thaisetthawatkul, A. Weinstock, S. L. Kerr, and M. E. Cohen Muromonab-CD3--Induced Neurotoxicity: Report of Two Siblings, One of Whom Had Subsequent Cyclosporin-Induced Neurotoxicity J Child Neurol, November 1, 2001; 16(11): 825 - 831. [Abstract] [PDF]

				O. Yoneda, T. Imai, S. Goda, H. Inoue, A. Yamauchi, T. Okazaki, H. Imai, O. Yoshie, E. T. Bloom, N. Domae, et al. Fractalkine-Mediated Endothelial Cell Injury by NK Cells J. Immunol., April 15, 2000; 164(8): 4055 - 4062. [Abstract] [Full Text] [PDF]

				C. Caliezi, W. A. Wuillemin, S. Zeerleder, M. Redondo, B. Eisele, and C. E. Hack C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in the Treatment of Diseases Other Than Hereditary Angioedema Pharmacol. Rev., March 1, 2000; 52(1): 91 - 112. [Abstract] [Full Text] [PDF]

				A. Q. Rafi-Janajreh, D. Chen, R. Schmits, T. W. Mak, R. L. Grayson, D. P. Sponenberg, M. Nagarkatti, and P. S. Nagarkatti Evidence for the Involvement of CD44 in Endothelial Cell Injury and Induction of Vascular Leak Syndrome by IL-2 J. Immunol., August 1, 1999; 163(3): 1619 - 1627. [Abstract] [Full Text] [PDF]

				L. Yao, C. Sgadari, K. Furuke, E. T. Bloom, J. Teruya-Feldstein, and G. Tosato Contribution of Natural Killer Cells to Inhibition of Angiogenesis by Interleukin-12 Blood, March 1, 1999; 93(5): 1612 - 1621. [Abstract] [Full Text] [PDF]

				A. Q. Rafi, A. Zeytun, M. J. Bradley, D. P. Sponenberg, R. L. Grayson, M. Nagarkatti, and P. S. Nagarkatti Evidence for the Involvement of Fas Ligand and Perforin in the Induction of Vascular Leak Syndrome J. Immunol., September 15, 1998; 161(6): 3077 - 3086. [Abstract] [Full Text] [PDF]

				J. L. Hornick, L. A. Khawli, P. Hu, M. Lynch, P. M. Anderson, and A. L. Epstein Chimeric CLL-1 Antibody Fusion Proteins Containing Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-2 With Specificity for B-Cell Malignancies Exhibit Enhanced Effector Functions While Retaining Tumor Targeting Properties Blood, June 15, 1997; 89(12): 4437 - 4447. [Abstract] [Full Text] [PDF]